Literature DB >> 1653392

Benzamide derivatives provide evidence for the involvement of a 5-HT4 receptor type in the mechanism of action of serotonin in frog adrenocortical cells.

S Idres1, C Delarue, H Lefebvre, H Vaudry.   

Abstract

We have previously shown that serotonin (5-HT) is a potent stimulator of corticosterone and aldosterone secretion by frog adrenocortical cells and we have demonstrated that the action of 5-HT is not mediated by the classical 5-HT receptor subtypes i.e. 5-HT1, 5-HT2 and 5-HT3. Recently, a non-classical 5-HT receptor (termed 5-HT4) has been characterized using 4-amino-5-chloro-2-methoxy-benzamide derivatives as serotonergic agonists. In the present report, we have investigated the possible involvement of the 5-HT4 receptor subtype in the mechanism of action of 5-HT on steroid secretion. Increasing concentrations of benzamide derivatives (zacopride, cisapride and BRL 24924) gave rise to a dose-related stimulation of corticosteroid production, zacopride being the most potent compound of this series to enhance steroidogenesis. Prolonged administration (230 min) of zacopride induced a rapid increase in corticosterone and aldosterone output followed by a gradual decline of corticosteroid secretion. During prolonged exposure of adrenal tissue to zacopride (10(-5) M), the corticotropic activity of 5-HT (10(-6) M) was totally abolished. The stimulatory effects of 5-HT and zacopride were abolished by the non-selective 5-HT3 antagonist ICS 205 930. In contrast methysergide, a 5-HT1 receptor antagonist, and MDL 72222, a selective 5-HT3 antagonist did not block zacopride-induced corticosteroid secretion. Both 5-HT and zacopride induced a dose-related increase in cAMP production by frog adrenal slices. Taken together, these results indicate that the stimulatory effect of 5-HT on frog adrenocortical tissue is mediated by activation of a 5-HT4 receptor subtype positively coupled to adenylate cyclase.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1653392     DOI: 10.1016/0169-328x(91)90068-9

Source DB:  PubMed          Journal:  Brain Res Mol Brain Res        ISSN: 0169-328X


  8 in total

Review 1.  Role of neurotransmitters and neuropeptides in the regulation of the adrenal cortex.

Authors:  C Delarue; V Contesse; S Lenglet; F Sicard; V Perraudin; H Lefebvre; M Kodjo; F Leboulenger; L Yon; N Gallo-Payet; H Vaudry
Journal:  Rev Endocr Metab Disord       Date:  2001-08       Impact factor: 6.514

2.  The action of SDZ 205,557 at 5-hydroxytryptamine (5-HT3 and 5-HT4) receptors.

Authors:  R M Eglen; R Alvarez; L G Johnson; E Leung; E H Wong
Journal:  Br J Pharmacol       Date:  1993-02       Impact factor: 8.739

3.  The guinea-pig distal colon--a sensitive preparation for the investigation of 5-HT4 receptor-mediated contractions.

Authors:  K A Wardle; G J Sanger
Journal:  Br J Pharmacol       Date:  1993-12       Impact factor: 8.739

4.  Serotonin increases interleukin-6 release and decreases tumor necrosis factor release from rat adrenal zona glomerulosa cells in vitro.

Authors:  P K Ritchie; H H Knight; M Ashby; A M Judd
Journal:  Endocrine       Date:  1996-12       Impact factor: 3.633

5.  Effects of a serotonin 5-HT(4) receptor antagonist SB-207266 on gastrointestinal motor and sensory function in humans.

Authors:  A E Bharucha; M Camilleri; S Haydock; I Ferber; D Burton; S Cooper; D Tompson; K Fitzpatrick; R Higgins; A R Zinsmeister
Journal:  Gut       Date:  2000-11       Impact factor: 23.059

6.  Immunohistochemical localization of bioactive peptides and amines associated with the chromaffin tissue of five species of fish.

Authors:  S G Reid; R Fritsche; A C Jönsson
Journal:  Cell Tissue Res       Date:  1995-06       Impact factor: 5.249

7.  Characterization of a serotonin receptor endogenous to frog melanophores.

Authors:  M N Potenza; M R Lerner
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1994-01       Impact factor: 3.000

Review 8.  Translating the promise of 5HT4 receptor agonists for the treatment of depression.

Authors:  Susannah E Murphy; Angharad N de Cates; Amy L Gillespie; Beata R Godlewska; Jessica C Scaife; Lucy C Wright; Philip J Cowen; Catherine J Harmer
Journal:  Psychol Med       Date:  2020-04-03       Impact factor: 7.723

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.